A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study

BACKGROUND: We sought to estimate the maximum tolerated or recommended phase 2 dose and describe the pharmacokinetics and toxicities of enzastaurin, an oral inhibitor of protein kinase Cβ, in children with recurrent central nervous system malignancies. METHODS: Enzastaurin was administered continuou...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Kilburn, Lindsay B., Kocak, Mehmet, Decker, Rodney L., Wetmore, Cynthia, Chintagumpala, Murali, Su, Jack, Goldman, Stewart, Banerjee, Anuradha, Gilbertson, Richard, Fouladi, Maryam, Kun, Larry, Boyett, James M., Blaney, Susan M.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Pediatric Neuro-Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4288513/
https://ncbi.nlm.nih.gov/pubmed/25431212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou114
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados